Welcome to our dedicated page for AINOS SEC filings (Ticker: AIMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Ainos Inc’s SEC archive for clues about progress in its AI-powered point-of-care tests or low-dose interferon trials quickly turns into a maze of biotech jargon and cross-referenced exhibits. Stock Titan brings Ainos Inc SEC filings explained simply: every 8-K material events explained, every exhibit summarized by AI, and critical trial milestones surfaced in seconds.
Need the latest Ainos Inc quarterly earnings report 10-Q filing? The moment it posts to EDGAR, we publish it with AI commentary that highlights R&D spend, cash runway, and VELDONA development costs. Ainos Inc Form 4 insider transactions real-time appear instantly, so you can track executive stock moves alongside our AI-driven sentiment notes. You’ll also find the Ainos Inc annual report 10-K simplified, the Ainos Inc proxy statement executive compensation sections clarified, and an at-a-glance dashboard for Ainos Inc earnings report filing analysis.
Investors often scan Ainos Inc insider trading Form 4 transactions for signals around clinical readouts, compare manufacturing head-count in the 10-K to POCT rollout plans, or watch liquidity metrics inside the 10-Q. Stock Titan connects those dots for you:
- AI keyword search across all filings for faster discovery
- Side-by-side quarter comparisons that make understanding Ainos Inc SEC documents with AI effortless
- Push alerts for Ainos Inc executive stock transactions Form 4
- Contextual notes on each Ainos Inc 8-K material events explained
Skip the PDFs and keep your focus on decisions, not document hunting.
Ainos, Inc. reported that it furnished its financial results for the quarter ended June 30, 2025 via a Current Report on Form 8-K dated August 13, 2025. The filing states a press release announcing those results is furnished as Exhibit 99.1 and that a Cover Page Interactive Data File is included as Exhibit 104. The report notes these materials are being furnished and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K identifies the company as a Texas corporation with principal offices in San Diego and lists its common stock (AIMD) and warrants (AIMDW) as Nasdaq-listed securities. The report is signed by Chun-Hsien Tsai, Chief Executive Officer. No financial amounts or results are included directly in the text of this Form 8-K.
Form 8-K – Item 8.01 Other Events
On 6-Aug-2025, Ainos, Inc. (Nasdaq: AIMD; AIMDW) reported that it has secured a US$2.1 million order from ASE Technology Holding Co., Ltd. to deploy the company’s AI Nose sensing platform in a semiconductor manufacturing environment. The related press release is provided as Exhibit 99.1.
The filing contains no revisions to previously issued financial statements, no earnings guidance, and no additional contractual terms beyond the order’s value and intended use. Other than standard cover information, Items 8.01 and 9.01 are the only sections with substantive disclosure.
FAQ
What is the current stock price of AINOS (AIMDW)?
